title: Natalizumab-associated central nervous system lymphoma?--another patient.
authors.forename: Mike
authors.initials: M
authors.lastname: Matzke
authors.forename: Stefanie
authors.initials: S
authors.lastname: Schreiber
authors.forename: Erck
authors.initials: E
authors.lastname: Elolf
authors.forename: Imke
authors.initials: I
authors.lastname: Metz
authors.forename: Christian
authors.initials: C
authors.lastname: Mawrin
authors.forename: Hans-Jochen
authors.initials: HJ
authors.lastname: Heinze
authors.forename: Michael
authors.initials: M
authors.lastname: Sailer
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D016543:Central Nervous System Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab